Orexin-A Hyperphagia: Hindbrain Participation in Consummatory Feeding Responses

• Published in: Endocrinology (Philadelphia) Vol. 150; no. 3; pp. 1202 - 1216
• Main Authors: Baird, John-Paul, Choe, Angela, Loveland, Jasmine L, Beck, Janine, Mahoney, Carrie E, Lord, Julia S, Grigg, Lindsay A
• Format: Journal Article
• Language: English
• Published: Chevy Chase, MD Endocrine Society 01.03.2009; The Endocrine Society
• Subjects: Animals; Appetite - drug effects; Behavior, Animal - drug effects; Biological and medical sciences; Dose-Response Relationship, Drug; Eating - drug effects; Feeding Behavior - drug effects; Feeding Behavior - physiology; Fundamental and applied biological sciences. Psychology; Hyperphagia - chemically induced; Infusion Pumps; Injections, Intraventricular; Intracellular Signaling Peptides and Proteins - administration & dosage; Intracellular Signaling Peptides and Proteins - pharmacology; Male; Neuropeptides - administration & dosage; Neuropeptides - pharmacology; Orexins; Rats; Rats, Sprague-Dawley; Rhombencephalon - drug effects; Rhombencephalon - physiology; Taste - drug effects; Vertebrates: endocrinology; Feeding behavior; Neuropeptide; Hyperphagia; Orexin; Feeding
• ISSN: 0013-7227; 1945-7170
• DOI: 10.1210/en.2008-0293

Orexin-A (ORXA) is an orexigenic neuropeptide produced by the lateral hypothalamus that increases food intake when injected into the brain ventricles or forebrain nuclei. We used a licking microstructure analysis to evaluate hindbrain and forebrain ORXA effects in intact and hindbrain-lesioned rats, to identify the motivational and anatomical bases of ORXA hyperphagia. Intact rats with cannulas in the fourth brain ventricle (4V) received vehicle (artificial cerebrospinal fluid) or ORXA (0.1, 0.4, 1, or 10 nm) injections before 90 min access to 0.1 m sucrose. Meal size and frequency were increased in a double-dissociated manner by the 1 and 10 nm doses, respectively. In experiment 2, 4V 1 nm ORXA was applied to rats offered solutions varied in caloric and gustatory intensity (water and 0.1 and 1 m sucrose). ORXA increased meal frequency for all tastants. ORXA increased meal size only for 0.1 m sucrose, by prolonging the meal without affecting early ingestion rate or lick burst size, suggesting that 4V ORXA influenced inhibitory postingestive feedback rather than taste evaluation. In experiment 3, rats with cannulas in the third ventricle (3V) received dorsal medullary lesions centered on the area postrema (APX group) or sham procedures, and licking for water and 0.1 and 1 m sucrose was evaluated after 1 nm 3V ORXA/artificial cerebrospinal fluid injections. The 3V ORXA increased 0.1 m sucrose meal size and meal frequency for all tastants in the sham group, as observed after 4V ORXA in experiment 2. In the APX group, 3V ORXA injections influenced meal frequency, but they no longer increased meal size. However, the APX rats increased meal size for 0.1 m sucrose after food and water deprivation and after 3V angiotensin II injection. They also showed meal size suppression after 3V injection of the melanocortin-3/4 receptor agonist melanotan II (1 nm). These findings suggest that the area postrema and subjacent nucleus of the solitary tract are necessary for increases in consummatory (meal size) but not appetitive (meal frequency) responses to 3V ORXA. The meal size increases may be due to reduced postingestive feedback inhibition induced by ORXA delivered to either the hindbrain or forebrain ventricles. Orexin-A increases meal size via gut feedback disinhibition, not enhanced gustatory evaluation. Medullary lesions abolish meal size but not frequency increases, indicating dissociable sites for orexin-A feeding actions.